Small molecule · Inhibitor of PARP-1 and PARP-2 · developed by AbbVie
Veliparib is a poly(ADP-ribose) polymerase (PARP)-1 and -2 inhibitor that potentiates the cytotoxicity of DNA-damaging agents by inhibiting DNA repair. It has no antiproliferative effects as a single agent at therapeutic concentrations. It is studied in multiple solid tumors including breast, ovarian, lung, and head and neck cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01366144 | Phase 1 | Breast Carcinoma | Active not recruiting | ABT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CarcinomaCarcinoma of Unknown PrimaryEndometrial CarcinomaEsophageal CarcinomaLiver FailureLung CarcinomaMalignant Head and Neck NeoplasmMalignant Testicular NeoplasmMelanomaMetastatic Malignant Solid NeoplasmOvarian CarcinomaRenal FailureUnresectable Malignant NeoplasmUrothelial Carcinoma